Sensitivity of KRAS-Mutated Non-Small Cell Lung Cancer to a Combination of MEK Kinase Inhibitor (Trametinib) and Autophagy Inhibitor (Hydroxychloroquine) in a Tissue Explant Model. Вопр. онкол. [Internet]. 2026 Mar. 11 [cited 2026 Oct. 14];72(1):OF-2403. Available from: https://voprosyonkologii.ru/index.php/journal/article/view/1-26-Sensitivity-of-KRAS-Mutated